The company secured a significant $125 million equity financing led by Gilde Healthcare (February 2024), indicating strong investor confidence and providing substantial resources to scale sales efforts and accelerate product adoption. With subsidiaries in Ireland, the US, Australia, Germany, and the Netherlands, and recent office expansions including the Dublin facility, Mainstay Medical is actively increasing its market presence and distribution channels across key regions.
Cyborg Score Rationale
Mainstay Medical has achieved FDA approval for its flagship product, secured substantial venture capital, and demonstrated clinical validation through five-year follow-up studies. However, the company remains private and early in commercial deployment, limiting scale and market validation.
Top Insights
ReActiv8 is the first and only FDA-approved restorative (not palliative) treatment for mechanical chronic low back pain, targeting the root cause via multifidus muscle neurostimulation
Strong clinical validation: five-year follow-up neuromodulation study published and RESTORE clinical trial enrollment completed as of early 2025
$125 million funding round (February 2024) from Gilde Healthcare signals investor confidence in market size and reimbursement potential
Expanding international footprint with operations across North America, Europe, and Australia; revenues reached approximately $15M as of September 2025
Named Competitors
Axonyx — Restorative neurostimulation for chronic low back pain
Recent Developments
(February 2024) Secured $125M equity financing led by Gilde Healthcare
(Early 2025) Completed enrollment of RESTORE clinical trial for ReActiv8 in the United States
(2025) Published first five-year neuromodulation follow-up study demonstrating long-term efficacy and safety
Open the full interactive Mainstay Medical Holdings Plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.